In August 2019, the Norwegian Institute of Public Health (NIPH) has released a single technology assessment report for molecular profiling panel – Prosigna for the assessment of expected benefit from chemotherapy in breast cancer, which aimed to investigate its prognostic accuracy, clinical effectiveness, and cost-effectiveness in patients diagnosed with breast cancer.
NIPH came to the following conclusions:
- There is probably a statistical association between Prosigna's risk prediction and the observed risk of distant recurrence after breast cancer. However, it is uncertain to what extent Prosigna contributes prognostic information that translates into better clinical results in terms of lower recurrence rates and reduced chemotherapy use;
- Conclusions about the cost-effectiveness of Prosigna cannot be made as there are no reliable data on chemotherapy use and clinical outcomes for patients who have or have not undergone Prosigna testing.
See the full health technology assessment report in English and Norwegian here.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.